Research Development Foundation
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
11
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Serine protease molecules and therapies (US 10,323,239) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jan 2, 2027The maintenance fee for Recombinant filaggrin polypeptides for cell importation (US 10,336,797) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 4 fees due Feb 4 to 20, 2027 · next Feb 4
- 3 fees due Apr 10 to 29, 2027 · next Apr 10
- 1 fee due Jun 3, 2027The maintenance fee for Apparatus and methods for optical coherence tomography and two-photon luminescence imaging (US 10,495,440) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 2 fees due Jul 7 to 30, 2027 · next Jul 7
- 2 fees due Aug 2 to 27, 2027 · next Aug 2
- 2 fees due Oct 16 to 19, 2027 · next Oct 16
Recent changes
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,605,033 | Immunoreactive glycoprotein GP19 of ehrlichia canis In force · From the USPTO record | In force | From the USPTO record | |
| US 9,814,768 | Immunoreactive glycoprotein GP19 of Ehrlichia canis In force · From the USPTO record | In force | From the USPTO record | |
| US 8,748,169 | Methods and compositions relating to restricted expression lentiviral vectors and their applications In force · From the USPTO record | In force | From the USPTO record | |
| US 9,605,036 | Vaccines and diagnostics for the ehrlichioses In force · From the USPTO record | In force | From the USPTO record | |
| US 9,850,295 | Vaccines and diagnostics for the ehrlichioses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,131,705 | Vaccines and diagnostics for the ehrlichioses In force · From the USPTO record | In force | From the USPTO record | |
| US RE46,254 | Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis In force · From the USPTO record | In force | From the USPTO record | |
| US 9,250,240 | Immunoreactive Ehrlichia p120/p140 epitopes and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,329,189 | Immunoreactive Ehrlichia p120/p140 epitopes and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,725,037 | Immunoglobulin Fc libraries In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 73: 3 patents in force now held by others · 136 lapsed for an unpaid fee · 168 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 10 abandoned · 50 no status recorded